myboxpra
- Abbott (NYSE:ABT) said on Tuesday that the U.S. FDA has approved it’s Tendyne transcatheter mitral valve replacement system for patients with mitral valve disease.
- The device is designed to treat people with severe mitral annular calcification, a condition where calcium builds up at the base of the mitral valve, preventing it from functioning properly.
- Tendyne offers a minimally invasive alternative for patients who are not eligible for open-heart surgery, providing a new treatment option for this high-risk group, the company said.
- ABT stock is up 1.43% in morning trade.
More on Abbott Laboratories
- Abbott Laboratories: Why Wall Street’s Skepticism Misses The Real Story
- The Growth Of Medical Devices Needs To Continue In Order To Invest In Abbott
- Abbott Labs’ Rally Is Well Deserved – Fade The Rally For Now
- Trump administration to review nutrients in baby formula
- Abbott gains after upcoming baby formula case thrown out